By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
The results of this meta-analysis by University of Cambridge-led team could have implications for LDL-C-lowering therapies.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The STARNET study found that cardiometabolic disease risk loci share cis- and trans-gene regulation.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.
DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.
The researchers found that older people with clear arteries had noticeably higher levels of CXCL5 compared with older people with more plaque buildup.
Independent research groups garnered evidence that mutations to the ANGPTL4 gene can lower blood triglyceride levels and reduce coronary artery disease risk.
Researchers found that reporting an incidental genetic finding doesn't cause patients extra anxiety and may lead to positive changes if the disease is actionable.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.